SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced the release of its first brochure for patients and caregivers about life with the SynCardia temporary Total Artificial Heart.
“By providing this brochure, we hope to address many of the common questions asked by patients and their families,” said Michael Garippa, SynCardia Chairman/CEO/President. “Implanting the Artificial Heart isn’t just a medical decision made by surgeons; it is also a family decision made by patients with the help of their loved ones. We want them to feel confident when making this vital decision about their medical care and their lives.”
The 12-page brochure was produced in a format that mimics the size and shape of an iPad. Readers learn about the progression of heart failure, the shortage of donor hearts and the role of the SynCardia Total Artificial Heart as a bridge to transplant. It also describes how the Total Artificial Heart works and what patients should expect before surgery, after the implant and during recovery.
In addition, the brochure introduces readers to the drivers that power the Total Artificial Heart. This section includes a checklist titled, “When Can I Go Home?” which provides an overview of the steps that need to be completed in order for patients to be discharged from the hospital to wait for a matching donor heart at home and in their communities using the Freedom portable driver.
Weighing 13.5 pounds, the Freedom driver is the world’s first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
Download the brochure as a PDF HERE.
For more information go to http://www.syncardia.com
